Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Daily Burden of CRSwNP

Daily Burden of CRSwNP

EOE Pediatric - Unmasking the Hidden Symptoms

EOE Pediatric - Unmasking the Hidden Symptoms

Atopic Dermatitis Pathophysiology: Breaking Down the Barrier

Atopic Dermatitis Pathophysiology: Breaking Down the Barrier

Importance of assessing key disease domains in EOE

Importance of assessing key disease domains in EOE

Daily Burden of CRSwNP

Daily Burden of CRSwNP

Importance of assessing key disease domains in EOE

Importance of assessing key disease domains in EOE

EOE Pediatric - Unmasking the Hidden Symptoms

EOE Pediatric - Unmasking the Hidden Symptoms

Airway Hyperresponsiveness<br/>in Asthma

Airway Hyperresponsiveness
in Asthma

Atopic Dermatitis Pathophysiology: Breaking Down the Barrier

Atopic Dermatitis Pathophysiology: Breaking Down the Barrier

Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Rare diseases : Dried Blood Spot (DBS)

Rare diseases : Dried Blood Spot (DBS)

DBS is a form of biosampling in which blood samples collected from a finger-prick lancet are blotted and dried on filter paper.1

These samples are then sent to analytical laboratories to be analysed using a variety of methods such as enzyme assays and polymerase chain reaction (PCR).2,3

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.